Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: yosi s who wrote (1277)	9/23/1998 12:25:00 PM
From: Ariella	Read Replies (1) \| Respond to of 1491

Indeed, hopefully they'll give more up-to-date info out on Alrex and Lotemax at this conference. What the analysts should come away with is that this is a compelling investment: -2 drugs already on market -a third drug based on the same compound due for NDA next year -two potential blockbuster compounds - HU-211 and Tamoxifen Methiodide - under development - $52 million in tax loss carryforwards - a probable cross into profitability by late 1999, a watershed experience in any biotech's existence